Date | Title | Description | |
---|---|---|---|
22 Jun 2021 | On significant placements in financial instruments | Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. | Download |
29 Apr 2021 | On business and financial situation | The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States. | Download |
12 Apr 2021 | On business and financial situation | The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. | Download |
02 Mar 2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
Pages
Date | Title | Description | |
---|---|---|---|
28 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 23 February 2022 and 25 February 2022 | Download |
23 Feb 2022 | Annual Corporate Governance Report | ROVI releases the 2021 Annual Corporate Governance Report | Download |
23 Feb 2022 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors | Download |
21 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 | Download |
15 Feb 2022 | On business and financial situation | ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
17 Mar 2016 | Acuerdos estratégicos con terceros | Enervit Nutrition, joint venture of ROVI and Enervit, will distribute nutritional products in Spain and Portugal | Download |
24 Feb 2016 | Información sobre resultados (2) | ROVI releases the press release related to the full year 2015 results | Download |
24 Feb 2016 | Información sobre resultados | ROVI releases the press release related to the full year 2015 results | Download |
24 Feb 2016 | Contratos de liquidez y contrapartida | The Company informs that it has signed a liquidity contract with JB Capital Markets, Sociedad de Valores, S.A.U. | Download |
24 Feb 2016 | Informe Anual de Gobierno Corporativo 2015 | ROVI releases the 2015 Annual Corporate Governance Report | Download |